Recently, in vitro inhibition of TGF-β signalling was shown to convert activated cardiac myofibroblasts from end-stage heart failure patients into quiescent cells, promoting depolymerisation of stress fibres, along with reduction of ECM synthesis and inflammatory cytokines 44. Here, TGFB1 is linked to heart failure.